Osteosarcoma (OS) is the most common primary malignant bone tumor, arising predominantly in teenagers and young adults from primitive transformed cells of mesenchymal origin. Despite decades of clinical research, outcomes for many patients remain poor: the global incidence is estimated at 4-5 cases per million per year, and the 5-year survival rate for patients with metastatic disease is less than 20%. Current standard treatment combines surgical resection with multi-agent chemotherapy, but a large fraction of patients develop resistance or relapse, underscoring the urgent need to understand the molecular drivers of disease.
The molecular complexity of OS: Unlike many cancers with well-defined driver mutations, osteosarcoma is characterized by highly variable and complex genomic rearrangements, heterogeneous gene expression patterns, and a high propensity for metastasis. This genetic chaos makes it difficult to identify consistent biomarkers for diagnosis, prognosis, or therapeutic targeting. Both protein-coding genes and non-coding RNAs, particularly microRNAs (miRNAs), have been implicated in OS biology, but their interactions and downstream effects remain incompletely mapped.
What are microRNAs? MicroRNAs are a class of small non-coding RNA molecules, approximately 20-25 nucleotides in length, that regulate gene expression post-transcriptionally by binding to the 3' untranslated regions (3' UTR) of target messenger RNAs (mRNAs). This binding typically results in mRNA degradation or translational repression. MiRNAs are estimated to regulate roughly 30% of all human genes, making them powerful modulators of cellular processes including proliferation, differentiation, and apoptosis. Abnormal miRNA expression has been documented across virtually all cancer types.
This 2019 study, published in Medical Science Monitor (volume 25, pages 4982-4991), applied RNA sequencing to simultaneously profile both miRNA and mRNA expression across osteosarcoma and adjacent non-cancerous tissue, then used bioinformatics and cell biology experiments to identify functionally important miRNA-mRNA pairs. The key finding was that miR-214-3p, an upregulated miRNA in OS, promotes tumor cell proliferation by suppressing UQCRC1, a nuclear-encoded mitochondrial protein.
The study enrolled 10 patients with primary osteosarcoma (age range 10-63 years, 4 males and 6 females) treated at the Department of Orthopedics of the Second Hospital of Jilin University between May 2017 and December 2018. All diagnoses were confirmed by pathological analysis, and patients were excluded if they had received radiotherapy or chemotherapy before surgery, or if they had concurrent congenital or other tumor-related diseases. For each patient, matched pairs of OS tumor tissue and adjacent non-cancerous (paracancerous) tissue were collected at the time of surgery, providing a paired internal control for expression comparisons.
Sequencing approach: RNA sequencing was performed on 3 of the 10 tissue pairs at Beijing Novogene Co., Ltd. A minimum of 3 micrograms of total RNA per sample was used to construct both miRNA and mRNA libraries. MiRNA libraries were prepared using the NEBNext Multiplex Small RNA Library Prep Set for Illumina, while mRNA libraries were prepared from rRNA-depleted RNA using the NEBNext Ultra Directional RNA Library Prep Kit. This dual-library approach enabled simultaneous profiling of both small non-coding RNAs and protein-coding transcripts from the same samples.
Validation in 10 patients: Expression levels of 8 selected miRNAs and 8 selected mRNAs (4 up-regulated and 4 down-regulated from each class) were validated in all 10 tissue pairs using real-time reverse transcription quantitative PCR (RT-qPCR). MiRNA and mRNA expression were normalized to U6 and GAPDH reference genes, respectively. Fold-change calculations used the standard 2-delta-delta-Ct method. All experiments were performed in triplicate to ensure reproducibility. Statistical comparisons between OS and normal tissue used unpaired Student's t-test, with the Benjamini-Hochberg method applied to correct for multiple comparisons (adjusted P-value threshold: 0.05).
Differential expression thresholds: Genes were considered significantly differentially expressed if they met a fold-change threshold of at least 2.0 (either up or down) with an adjusted P-value less than 0.05. This conservative dual threshold reduces the likelihood of false-positive discoveries while still capturing biologically meaningful expression changes across the tumor-normal comparison.
After identifying differentially expressed genes from the sequencing data, the authors applied a multi-layered bioinformatics pipeline to move from a list of dysregulated transcripts to an understanding of their biological roles and interactions. This pipeline is a standard approach in transcriptomics studies and provides the functional context needed to prioritize candidates for experimental follow-up.
Gene Ontology (GO) analysis: GO annotation was used to categorize the functions of differentially expressed genes across three domains: Biological Process (BP), Cellular Component (CC), and Molecular Function (MF). Among upregulated genes in OS, the most significantly enriched GO terms included cell growth and maintenance (BP), lysosomal localization (CC), and extracellular matrix structural constituent activity (MF). For downregulated genes, the dominant terms were energy pathways (BP), mitochondrion (CC), and oxidoreductase activity (MF). The enrichment of downregulated genes in mitochondria-associated categories pointed toward disrupted mitochondrial function as a feature of OS biology.
KEGG pathway enrichment: Pathway analysis using the Kyoto Encyclopedia of Genes and Genomes (KEGG) database identified 54 significantly enriched pathways overall (adjusted P-value below 0.05). Among the most significantly upregulated pathways were proteoglycans in cancer and the PI3K/AKT signaling pathway, a well-established oncogenic pathway in OS and other cancers. Several upstream regulatory genes known to dysregulate OS through PI3K/AKT signaling were represented in this enrichment, including genes implicated in resistance to standard chemotherapy agents like cisplatin and doxorubicin.
Protein-protein interaction (PPI) network: Differentially expressed mRNA-encoded proteins were mapped onto a PPI network using the STRING database and visualized using OmicsBean. The resulting network comprised 410 interactions (edges) among 40 proteins (nodes), organized across 10 pathways. UQCRC1 (ubiquinol-cytochrome c reductase core protein 1) emerged as the most highly connected node, interacting with 7 of the 21 hub pathways in the network. This central position in the interaction map flagged UQCRC1 as a critical regulatory gene worthy of experimental investigation.
RNA sequencing of the 3 paired OS and paracancerous tissues yielded a large-scale portrait of transcriptional dysregulation in osteosarcoma. In total, 184 miRNAs were identified as significantly differentially expressed, with 82 upregulated and 102 downregulated in OS tissue relative to adjacent normal bone. At the mRNA level, 2,501 transcripts showed significant differential expression: 1,320 were upregulated and 1,181 were downregulated (all meeting the fold-change greater than 2.0 and adjusted P-value less than 0.05 criteria). Hierarchical clustering analysis confirmed that the miRNA and mRNA expression profiles were clearly distinguishable between OS and paracancerous tissues, indicating that the transcriptional changes are consistent and tumor-specific rather than random noise.
Validated upregulated miRNAs: Among the top differentially expressed miRNAs validated by RT-qPCR in all 10 patients, 4 upregulated miRNAs were confirmed: miR-181b-3p, miR-301b-3p, miR-199a-5p, and miR-214-3p. These 4 were selected based on their rank in the sequencing data and known relevance in cancer biology. MiR-199a-5p is particularly notable because it has previously been identified as a noninvasive serum biomarker for detecting and monitoring osteosarcoma. MiR-214-3p was the focus of this study's experimental follow-up, given its ranking and the availability of a plausible target gene (UQCRC1) identified through PPI network analysis.
Validated downregulated miRNAs: Four downregulated miRNAs were also confirmed by RT-qPCR: miR-378i, miR-133a-5p, miR-885-5p, and miR-183-3p. Of these, miR-133a-5p has established tumor suppressor roles in multiple cancers including prostate, colorectal, esophageal, and gastric cancers, and miR-885-5p has previously been shown to suppress OS proliferation, migration, and invasion through regulation of beta-catenin signaling. The consistent downregulation of these known tumor suppressors in OS tissue corroborates the reliability of the sequencing data.
Validated mRNA changes: At the mRNA level, 4 upregulated transcripts were confirmed in patients: GIT2, COL11A2, PANX3, and PTN. Four downregulated mRNAs were also confirmed, with UQCRC1 among the most significantly reduced genes in OS tissue and cell lines. The dual downregulation of UQCRC1 at the mRNA level (from sequencing) and protein level (implied by pathway network analysis) made it a strong candidate target gene for a functionally relevant upregulated miRNA.
Having identified UQCRC1 as a central hub gene in the PPI network and confirmed its downregulation in OS tissue, the authors sought to identify which miRNA might be responsible for suppressing UQCRC1 expression. They used TargetScan Human 7.2, a widely used computational tool that predicts miRNA target sites in 3' UTR sequences based on seed sequence complementarity and conservation across species. TargetScan predicted 60 candidate miRNAs as potential regulators of UQCRC1.
Narrowing to 5 candidates: Of the 60 predicted miRNAs, 5 were detected as differentially expressed in the OS sequencing data: miR-214-3p, miR-512-3p, miR-3688-5p, miR-6866-5p, and miR-520a-3p. Since UQCRC1 was confirmed to be downregulated in OS, the authors focused exclusively on upregulated miRNAs among these 5 candidates (applying the logic that an upregulated miRNA would be most likely to suppress a downregulated target gene). Only miR-214-3p was upregulated in OS; the other 4 candidates were downregulated. This filtering process left a single high-priority candidate for experimental validation.
Luciferase reporter confirmation: To directly confirm that miR-214-3p binds the 3' UTR of UQCRC1, a dual luciferase reporter assay was performed. The predicted miR-214-3p binding site in the UQCRC1 3' UTR was cloned downstream of a luciferase reporter construct. When miR-214-3p was co-transfected with the wild-type reporter, luciferase activity was significantly reduced compared to controls, confirming direct binding. When the putative binding site was mutated, this suppression was abolished, demonstrating specificity. This is the gold-standard assay for confirming a miRNA-target relationship at the molecular level.
Functional miRNA manipulation in cells: MiR-214-3p function was further tested in MG63 osteosarcoma cells using synthetic miRNA mimics (to overexpress miR-214-3p) and inhibitors (to knock down miR-214-3p). RT-qPCR confirmed that when miR-214-3p was overexpressed using mimics, UQCRC1 mRNA levels were substantially reduced. Conversely, when miR-214-3p was knocked down using the inhibitor, UQCRC1 expression was upregulated. This bidirectional relationship between miR-214-3p levels and UQCRC1 expression confirmed the functional regulatory axis in living cells.
The functional consequence of miR-214-3p activity on osteosarcoma cell growth was assessed using the Cell Counting Kit-8 (CCK-8) assay, a colorimetric method for measuring cell viability and proliferation based on the conversion of WST-8 dye by cellular dehydrogenases. MG63 osteosarcoma cells were seeded at a density of 3,000 cells per well in 96-well plates, then transfected with miR-214-3p mimics, miR-214-3p inhibitor, or the respective negative controls. Cell proliferation was measured by optical density at 450 nm at 24-hour intervals following transfection.
Proliferation results: Cells transfected with miR-214-3p mimics showed significantly greater proliferation than non-transfected control cells at days 3, 4, 5, and 6 after transfection. The proliferative advantage emerged progressively over time, consistent with a cumulative suppression of growth-inhibitory genes downstream of UQCRC1. In contrast, cells transfected with the miR-214-3p inhibitor exhibited significantly decreased proliferation compared to controls over the same time course, demonstrating that endogenous miR-214-3p contributes to the proliferative capacity of MG63 cells. All experiments were performed in triplicate to confirm reproducibility.
Biological significance of UQCRC1 suppression: UQCRC1 is a nuclear-encoded protein that localizes to the inner mitochondrial membrane and forms part of Complex III of the electron transport chain. Complex III is responsible for transferring electrons from ubiquinol to cytochrome c, a critical step in oxidative phosphorylation and ATP production. The role of UQCRC1 in cancer is context-dependent: it is upregulated in breast and ovarian cancers but significantly downregulated in clear cell renal cell carcinoma and gastric cancer, and now in osteosarcoma. This context-specificity suggests that UQCRC1 exerts tissue-type and tumor-microenvironment-dependent effects on metabolism and cell growth.
Mechanistic interpretation: The simplest interpretation is that miR-214-3p drives OS cell proliferation by suppressing UQCRC1, which disrupts mitochondrial Complex III function and shifts cellular energy metabolism. Some cancers benefit from altered mitochondrial activity by redirecting precursors toward biosynthetic pathways that support rapid cell division. However, the precise downstream metabolic or signaling changes that connect UQCRC1 loss to accelerated proliferation in OS remain to be mechanistically characterized in future work.
Small sequencing cohort: RNA sequencing was performed on only 3 pairs of OS and paracancerous tissue. While the 10-patient RT-qPCR validation cohort provides some additional support, the initial expression profiling dataset is too small to draw definitive conclusions about the prevalence and magnitude of miRNA and mRNA dysregulation across the broader osteosarcoma patient population. Osteosarcoma displays considerable genomic heterogeneity between patients, meaning that a 3-sample discovery set may not capture the full spectrum of expression patterns. Larger multi-center sequencing cohorts would be required to determine which of the 184 miRNAs and 2,501 mRNAs identified here are consistently dysregulated across OS subtypes and demographic groups.
Incomplete target landscape: While the study identified and validated UQCRC1 as a direct target of miR-214-3p, the precise functional consequences of UQCRC1 downregulation on OS cell biology were not fully explored. The CCK-8 assay quantifies overall proliferative output but does not distinguish whether the effect is driven by accelerated cell cycle progression, reduced apoptosis, or changes in metabolic substrate utilization. Western blot confirmation of UQCRC1 protein level changes (not just mRNA) would strengthen the mechanistic argument, and downstream proteomic or metabolomic profiling would help clarify which mitochondrial or signaling pathways are affected. Additionally, the other 59 predicted miRNA targets of UQCRC1 and the other miRNAs that regulate OS cell biology were not investigated.
Single cell line and in vitro limitations: Proliferation assays were conducted exclusively in the MG63 osteosarcoma cell line. This is a standard cell line for OS research but represents only one of many OS cell subtypes. Results from a single cell line cannot necessarily be extrapolated to primary OS cells, patient-derived xenograft models, or the in vivo tumor microenvironment. The tumor microenvironment, including stromal cells, immune infiltrates, and hypoxic niches, significantly influences miRNA biology and metabolic gene expression in ways that standard cell culture cannot replicate. Animal model validation (xenograft or genetic OS mouse models) would be an important next step.
Clinical translation gap: The study does not address whether miR-214-3p expression levels in patient tissue or serum correlate with clinical outcomes such as response to chemotherapy, metastasis-free survival, or overall survival. Establishing these associations would be necessary before miR-214-3p could be considered as a biomarker or a therapeutic target in the clinical setting.
miR-214-3p as a candidate therapeutic target: Given that miR-214-3p promotes OS cell proliferation, pharmacological inhibition of this miRNA represents a conceptually attractive therapeutic strategy. Anti-miRNA oligonucleotides (antagomirs) chemically modified for stability and cellular uptake can suppress endogenous miRNA activity in vivo. MiR-214 has already been investigated in this context in other cancers, including melanoma, where it drives metastasis, and cervical cancer, where its inhibition reduces cell growth. Whether antagomir-214-3p could be delivered effectively to OS tumors, including through systemic or local delivery routes, would need to be tested in preclinical animal models first.
UQCRC1 restoration as an alternative approach: Rather than targeting miR-214-3p directly, restoring UQCRC1 expression in OS cells using viral vector-based gene delivery or small molecule modulators of Complex III activity could potentially counteract the proliferative effect of miR-214-3p overexpression. This approach would need careful evaluation for specificity, since UQCRC1 plays different roles in different cancer types and its restoration could have unpredictable effects in tumor microenvironments with altered metabolic states.
Serum miR-214-3p as a liquid biopsy biomarker: Several miRNAs identified in this study have prior evidence for detectability in patient serum, including miR-199a-5p, which has been identified as a noninvasive serum biomarker for OS detection and monitoring. Given that circulating miRNAs are packaged in exosomes and protein complexes that protect them from degradation, miR-214-3p may similarly be measurable in OS patient blood. A prospective study measuring serum miR-214-3p before and after surgery, or across chemotherapy cycles, could evaluate its utility for early detection, disease monitoring, and response assessment without invasive tissue biopsies.
Multi-omics integration: The full power of this dataset, encompassing 184 differentially expressed miRNAs and 2,501 differentially expressed mRNAs, has not been exhausted by the single miR-214-3p/UQCRC1 axis investigated here. Systematic construction and experimental validation of the complete miRNA-mRNA regulatory network in OS, potentially integrated with proteomic and metabolomic data, could reveal additional functionally important axes and identify synergistic targets. Machine learning approaches applied to the combined expression dataset could also identify multi-gene signatures for predicting chemotherapy response or metastatic risk, which would have direct clinical value given the difficulty of stratifying OS patients under current practice.